NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company
focused on unique targeted therapeutics for patients suffering from
dermatological indications ranging from atopic dermatitis,
psoriasis and acne along with gene therapy treatment for
asthmatics, today announced preliminary, preclinical data for its
lupus treatment for patients suffering with Cutaneous Lupus
Erythematous (CLE), a chronic autoimmune skin disease.
"The preliminary data of our
study is a positive step toward underlining the transformative
potential of AEA-loaded Z-pods™ in patients suffering from CLE,"
stated Mr. Robb Knie, CEO of Hoth Therapeutics, Inc. "We
are pleased with the results we have made in the development of our
lupus treatment since announcing our strategy earlier this
year with our partner Zylö Therapeutics. At the
conclusion of this study we look forward to the next steps in
bringing this treatment to those patients in need."
Mr. Scott Pancoast, CEO of Zylö,
added, "These compelling results, coupled with the data from a
preliminary study conducted at Einstein College of Medicine,
clearly warrant further investigation of this novel approach to
treating cutaneous manifestations of lupus."
Hoth owns an exclusive license to develop Anandamide-loaded
Z-pods™ for the treatment of CLE in North America. Anandamide,
generally referred to as AEA, is one of the cannabinoids that the
human body makes naturally. The Company also possesses rights
related to geographic expansion and to follow-on indications such
as psoriasis and rheumatoid arthritis.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing new generation therapies for
dermatological disorders. HOTH's pipeline has the potential to
improve the quality of life for patients suffering from indications
including atopic dermatitis, chronic wounds, psoriasis, asthma and
acne. To learn more, please
Forward Looking Statements
This press release includes "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements that relate to the advancement and
development of the BioLexa Platform, the commencement of clinical
trials, the availability of data from clinical trials and other
information that is not historical information. When used herein,
words such as "anticipate", "being", "will", "plan", "may",
"continue", and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Hoth's current expectations and various assumptions.
Hoth believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. Hoth may not realize
its expectations, and its beliefs may not prove correct. Actual
results could differ materially from those described or implied by
such forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Investor Relations Contact:
Phone: (646) 756-2997
KCSA Strategic Communications
Valter Pinto, Managing
View original content to download
SOURCE Hoth Therapeutics, Inc.